Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions DOI Open Access
M H Miran Beygi, Salma Ahi, Samaneh Zolghadri

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(14), P. 2220 - 2220

Published: July 11, 2024

Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting that affects millions of people around the world. It best identified with hepatic fat build-up ultimately leads to inflammation and damage. The classification nomenclature NAFLD have long been controversial topic, until 2020 when group international experts recommended substituting MAFLD (metabolic dysfunction-associated FLD). was then terminologically complemented in 2023 by altering it MASLD, i.e., metabolic steatotic (MASLD). Both MASLD terminologies comprise element disorder, as they offer diagnostic benchmarks are embedded risk factors underlie disease. (as multisystemic disease) provides comprehensive definition includes larger population patients who at morbidity mortality, well adverse cardiovascular diabetes outcomes. highlights risks lean or normal weight individuals, factor has not accentuated discussed previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, exercise therapies extensively studied MASLD. Nutrition plays vital role managing both conditions, where centralizing on diet rich whole vegetables, fruits, foods, healthy fats, proteins, specific nutrients (e.g., omega-3 acids fibers) can improve insulin resistance reduce inflammation. Thus, essential understand nutrition these conditions work develop an individualized plan for optimal health. This review discusses prevention strategies NAFLD/MAFLD/MASLD management, particular attention correction.

Language: Английский

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis DOI
Alessandro Mantovani, Alessandro Csermely,

Graziana Petracca

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2021, Volume and Issue: 6(11), P. 903 - 913

Published: Sept. 21, 2021

Language: Английский

Citations

398
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach DOI
Giovanni Targher, Herbert Tilg, Christopher D. Byrne

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2021, Volume and Issue: 6(7), P. 578 - 588

Published: May 4, 2021

Language: Английский

Citations

377
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States DOI
Donghee Kim, Peter Konyn,

Keeryth K. Sandhu

et al.

Journal of Hepatology, Journal Year: 2021, Volume and Issue: 75(6), P. 1284 - 1291

Published: Aug. 8, 2021

Language: Английский

Citations

333
Global Impacts of Western Diet and Its Effects on Metabolism and Health: A Narrative Review DOI Open Access
Vicente Javier Clemente‐Suárez, Ana Isabel Beltrán-Velasco, Laura Redondo-Flórez

et al.

Nutrients, Journal Year: 2023, Volume and Issue: 15(12), P. 2749 - 2749

Published: June 14, 2023

The Western diet is a modern dietary pattern characterized by high intakes of pre-packaged foods, refined grains, red meat, processed high-sugar drinks, candy, sweets, fried conventionally raised animal products, high-fat dairy and high-fructose products. present review aims to describe the effect on metabolism, inflammation, antioxidant status; impact gut microbiota mitochondrial fitness; cardiovascular health, mental cancer; sanitary cost diet. To achieve this goal, consensus critical was conducted using primary sources, such as scientific articles, secondary including bibliographic indexes, databases, web pages. Scopus, Embase, Science Direct, Sports Discuss, ResearchGate, Web were used complete assignment. MeSH-compliant keywords “Western diet”, “inflammation”, “metabolic health”, fitness”, “heart disease”, “cancer”, “oxidative stress”, “mental “metabolism” used. following exclusion criteria applied: (i) studies with inappropriate or irrelevant topics, not germane review’s focus; (ii) Ph.D. dissertations, proceedings conferences, unpublished studies. This information will allow for better comprehension nutritional behavior its an individual’s metabolism well national systems. Finally, practical applications derived from are made.

Language: Английский

Citations

292
MAFLD: How is it different from NAFLD? DOI Creative Commons
Cameron Gofton,

Yadhavan Upendran,

Ming‐Hua Zheng

et al.

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(Suppl), P. S17 - S31

Published: Nov. 29, 2022

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer related systemic metabolic dysregulation. The name change from nonalcoholic (NAFLD) MAFLD comes with a simple set of criteria enable easy diagnosis at bedside for general medical community, including primary care physicians. Since introduction term, there have been key areas which superiority over traditional NAFLD terminology has demonstrated, risk and extrahepatic mortality, associations, identifying high-risk individuals. Additionally, adopted by number leading pan-national national societies due its concise diagnostic criterion, removal requirement exclude concomitant diseases, reduction stigma associated this condition. current article explores differences between diagnosis, benefit, some potential limitations, how opened up new fields research.

Language: Английский

Citations

245
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement DOI
Mohammed Eslam, Naim Alkhouri, Pietro Vajro

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2021, Volume and Issue: 6(10), P. 864 - 873

Published: Aug. 6, 2021

Language: Английский

Citations

208
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) DOI Creative Commons
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Aug. 13, 2022

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading cause of liver disease worldwide. NASH, an advanced form NAFL, can be progressive and more susceptible to developing cirrhosis hepatocellular carcinoma. Currently, lifestyle interventions are most essential effective strategies for preventing controlling NAFL without development fibrosis. While there still limited appropriate drugs specifically treat NAFL/NASH, growing progress is being seen in elucidating pathogenesis identifying therapeutic targets. In this review, we discussed recent developments etiology prospective targets, as well pharmacological candidates pre/clinical trials patents, with a focus on diabetes, hepatic lipid metabolism, inflammation, Importantly, evidence elucidates that disruption gut-liver axis microbe-derived metabolites drive NAFL/NASH. Extracellular vesicles (EVs) act signaling mediator, resulting accumulation, macrophage stellate cell activation, further promoting inflammation fibrosis progression during Targeting gut microbiota or EVs may serve new treatment Finally, other mechanisms, such therapy genetic approaches, also have enormous potential. Incorporating different mechanisms personalized medicine improve efficacy better benefit patients

Language: Английский

Citations

203
Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals DOI Open Access
Kai En Chan,

Tiffany Jia Ling Koh,

Ansel Shao Pin Tang

et al.

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2022, Volume and Issue: 107(9), P. 2691 - 2700

Published: May 19, 2022

Abstract Background and Aims Metabolic-associated fatty liver disease (MAFLD) was proposed as a better definition of nonalcoholic (NAFLD) to encompass the metabolic dysregulation associated with NAFLD. This redefinition challenges our understanding disease. Hence, this study sought conduct an updated analysis prevalence, clinical characteristics, factors MAFLD, further sensitivity done based on lean nonobese MAFLD individuals. Methods Medline Embase databases were searched include articles MAFLD. Meta-analysis proportions conducted using generalized linear mix model. Associating evaluated in conventional pairwise meta-analysis Results From pooled involving 3 320 108 individuals, overall prevalence 38.77% (95% CI 32.94% 44.95%); 5.37% 4.36% 6.59%) 29.78% 26.06% 33.79%) respectively, had Metabolic complications such hypertension [odds ratio (OR) 2.63, 95% 1.85 3.74, P < 0.0001 OR 2.03; 1.74 2.38, 0.0001, respectively] diabetes (OR 3.80, 2.65 5.43, 3.46, 2.81 4.27, respectively) found significant associating Conclusions supports previous studies reporting affect more than third global population. While exploration pathogenic basis without is required, emphasis management concomitant can improve multidisciplinary efforts managing complex

Language: Английский

Citations

197
Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD DOI Creative Commons
Vy H. Nguyen, Michael H. Le, Ramsey Cheung

et al.

Clinical Gastroenterology and Hepatology, Journal Year: 2021, Volume and Issue: 19(10), P. 2172 - 2181.e6

Published: May 23, 2021

Language: Английский

Citations

175
The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study DOI Open Access
Jiarong Xie, Hangkai Huang, Zhening Liu

et al.

Hepatology, Journal Year: 2022, Volume and Issue: 77(3), P. 949 - 964

Published: Aug. 16, 2022

Background and Aims: Early identification of modifiable risk factors is essential for the prevention nonalcoholic fatty liver disease (NAFLD). We aimed to systematically explore relationships between genetically predicted NAFLD. Approach Results: applied univariable multivariable Mendelian randomization analyses 35 also evaluated combined results in three independent large genome‐wide association studies. Genetically alcohol frequency, elevated serum levels enzymes, triglycerides, C‐reactive protein, obesity traits, including body mass index, waist circumference, fat mass, were associated with increased risks NAFLD (all p < 0.05). Poor physical condition had a suggestive (odds ratio [OR] = 2.63, 0.042). instrumented type 2 diabetes (T2DM), hypothyroidism, hypertension all NAFLD, ORs (95% confidence interval) 1.508 (1.20–1.90), 13.08 (1.53–111.65), 3.11 (1.33–7.31) 1‐U increase log‐transformed odds, respectively. The positive associations T2DM remained significant analyses. from discovery two replication datasets further confirmed that poor condition, T2DM, significantly whereas higher education high‐density lipoprotein cholesterol (HDL‐cholesterol) could lower risk. Conclusions: an HDL‐cholesterol decreased

Language: Английский

Citations

163